Orthocell announces research collaboration

Company News

by Jessica Amir

Orthocell Limited (ASX:OCC) has entered into a research collaboration with Johnson and Johnson for its stem cell products.

The product, Ortho-ATI, is a non-surgical approach that treats resistant tendons and ligament injuries.

The companies will conduct a collaborative study in the first quarter of 2017 and conduct a trial with leading orthopaedic surgeons.

Ortho-ATI is available in Australian and New Zealand.

Orthocell posted a net loss $3.8 million at 30 June 2016.

Jessica Amir

Finance News Network
Jessica is the head of news and a senior finance journalist and presents bulletins including the Market Outlook, Market at Midday and Market Wrap. She also interviews ASX CEOs and leading fund managers. She joined FNN in January 2017 with over six years of broadcast journalism experience including with Sky News Business, ABC 1, ABC's The Business and ABC24. She’s also worked as a TV reporter for Prime 7 and WIN News. Jessica has worked in financial planning for over six years with leading wealth managers and in real estate.